TOSYMRA

Peak

sumatriptan

NDANASALSPRAY
Approved
Jan 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20

Mechanism of Action

Serotonin 1b Receptor Agonists

Pharmacologic Class:

Serotonin-1b and Serotonin-1d Receptor Agonist

Clinical Trials (5)

NCT04355845Phase 1Completed

A STUDY TO EVALUATE THE EFFECT OF PF-06651600 ON PHARMACOKINETICS OF SINGLE DOSE SUMATRIPTAN IN HEALTHY PARTICIPANTS.

Started Jun 2020
10 enrolled
Healthy Volunteers
NCT03310411Phase 1Completed

A Study of Lasmiditan When Given With Sumatriptan in Healthy Participants

Started Oct 2017
40 enrolled
Healthy
NCT03076970Phase 1Completed

Effect of Single Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan in Healthy Participants

Started Mar 2017
42 enrolled
Migraine
NCT02741310Phase 1Completed

Study to Evaluate the Effect of Erenumab on Blood Pressure When Given Concomitantly With Subcutaneous Sumatriptan

Started Feb 2016
34 enrolled
Healthy Subjects
NCT01381523N/ACompleted

A Combination Product of Sumatriptan and Naproxen Sodium Versus Single-entity Oral Triptans: An Analysis of Real World Data

Started Nov 2010
1 enrolled
Migraine Disorders

Loss of Exclusivity

LOE Date
Jul 19, 2031
65 months away
Patent Expiry
Jul 19, 2031

Patent Records (5)

Patent #ExpiryTypeUse Code
8268791
May 9, 2026
Product
8440631
May 9, 2026
Product
U-1719
9283280
May 9, 2026
Product
9974770
Jun 16, 2030
Product
U-1719
11337962
Jun 16, 2030
Product
U-1719